HiGHS2 risk prediction model for VTE in long-term allogeneic BMT survivors
| Variable . | β estimation . | SE . | HR . | 95% CI . | P . | Risk score . |
|---|---|---|---|---|---|---|
| History of stroke | 1.0755 | 0.5189 | 2.93 | (1.06-8.10) | .038 | 3 |
| Chronic GVHD | 0.3517 | 0.2527 | 1.42 | (0.87-2.33) | .164 | 1 |
| Hypertension | 0.6845 | 0.2579 | 1.98 | (1.20-3.29) | .008 | 2 |
| Sex, male | 0.6138 | 0.2578 | 1.85 | (1.11-3.06) | .017 | 2 |
| Stem cell source, PBSC | 1.0394 | 0.2739 | 2.83 | (1.65-4.84) | .0001 | 3 |
| Variable . | β estimation . | SE . | HR . | 95% CI . | P . | Risk score . |
|---|---|---|---|---|---|---|
| History of stroke | 1.0755 | 0.5189 | 2.93 | (1.06-8.10) | .038 | 3 |
| Chronic GVHD | 0.3517 | 0.2527 | 1.42 | (0.87-2.33) | .164 | 1 |
| Hypertension | 0.6845 | 0.2579 | 1.98 | (1.20-3.29) | .008 | 2 |
| Sex, male | 0.6138 | 0.2578 | 1.85 | (1.11-3.06) | .017 | 2 |
| Stem cell source, PBSC | 1.0394 | 0.2739 | 2.83 | (1.65-4.84) | .0001 | 3 |
Hypertension, stroke, and chronic GVHD were evaluated at 2 years after BMT.
SE, standard error.